Actively Recruiting
A Trial of SHR-4849 in Advanced Solid Tumors
Led by Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Updated on 2025-03-05
80
Participants Needed
1
Research Sites
126 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-4849 injection in Advanced Solid Tumors. To explore the reasonable dosage of SHR-4849 for Advanced Solid Tumors.
CONDITIONS
Official Title
A Trial of SHR-4849 in Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provided informed consent before starting study procedures
- Age between 18 and 75 years old at consent
- Confirmed advanced solid tumors by tissue or cell testing
- At least one measurable tumor lesion
- ECOG performance status of 0 or 1
- Life expectancy of at least 3 months
- Adequate organ function
- Use of effective contraception if of child-bearing potential from consent until 6 months after last dose
You will not qualify if you...
- Active central nervous system metastases
- History of other malignant tumors within 5 years before first dose
- Uncontrolled cancer pain
- Severe heart disease
- Significant bleeding problems
- Uncontrolled fluid buildup in chest, abdomen, or around the heart
- Suspected interstitial lung disease
- Serious infection within 4 weeks before first dose
- Known HIV or active hepatitis B or C infection
- Unrecovered side effects from previous cancer treatments above grade 1
- Anti-cancer treatment within 4 weeks before first dose
- Major surgery within 4 weeks before first dose
- Planned or recent live vaccinations within 28 days before first dose
- Pregnancy, breastfeeding, or plans to become pregnant during study
- Allergy to any component of SHR-4849
- Alcohol or drug abuse, serious medical or mental illness affecting safety or data
- Other conditions judged by investigator to interfere with study or safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Jilin Cancer Hospital
Jilin, Changchun, China
Actively Recruiting
Research Team
W
wei Hou
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here